| 2024-12-04 | -0.33 % |
|
| 2024-12-03 | -1.25 % |
|
| 2024-11-12 | -1.14 % |
|
| 2024-11-08 | -3.88 % |
|
| 2024-11-01 | +0.48 % |
|
| 2024-10-30 | -0.36 % |
|
| 2024-10-24 | +0.71 % |
|
| 2024-10-23 | -0.33 % |
|
| 2024-10-16 | +0.3 % |
|
| 2024-10-15 | -0.7 % |
|
| 2024-10-10 | -2.14 % |
|
| 2024-10-09 | +1.94 % |
|
| 2024-10-08 | +3.77 % |
|
| 2024-10-07 | -1.51 % |
|
| 2024-10-04 | +3.53 % |
|
| 2024-10-01 | -2.79 % |
|
| 2024-09-30 | -2.42 % |
|
| 2024-09-24 | -0.05 % |
|
| 2024-09-12 | +0.28 % |
|
| 2024-09-03 | -0.24 % |
|
| 2024-08-14 | +2.96 % |
|
| 2024-08-13 | -6.55 % |
|
| 2024-08-07 | -0.89 % |
|
| 2024-08-06 | +6.58 % |
- Baxter International Inc. (NYSE:BAX) experienced a 6.58% increase in its stock price following strong second-quarter 2024 results that exceeded expectations, driven by sales growth across multiple segments, an optimistic full-year sales outlook, and strategic initiatives, including the planned separation of its Kidney Care business.
- Baxter International (BAX) stock rose by 6.58% due to positive market sentiment surrounding healthcare stocks, possibly fueled by investor confidence in the company’s recent performance and outlook.
- Baxter International Inc. (BAX) stock rose 6.58% following the company's better-than-expected second-quarter results, which included an adjusted EPS of $0.68 and sales of $3.812 billion that exceeded both consensus estimates and management guidance, indicating strong performance across all segments and positive growth outlook for 2024.
- Baxter International (BAX) stock increased by 6.58% last night likely due to positive investor sentiment or recent favorable developments concerning the company's financial metrics, market performance, or product announcements, though the article itself does not specify the exact reasons for the rise.
- Baxter International's stock (BAX) rose 6.58% after the company reported better-than-expected second-quarter earnings, with adjusted EPS of $0.68 and sales of $3.812 billion exceeding analyst expectations and its own guidance, alongside optimistic future projections for sales growth and adjusted EPS.
|
| 2024-08-05 | -1.79 % |
|
| 2024-07-23 | -0.25 % |
|
| 2024-07-17 | +0.39 % |
|
| 2024-07-15 | -3.82 % |
- Morgan Stanley downgraded Baxter International (NYSE:BAX) stock to Underweight, citing concerns about the company's financial outlook post-acquisition of Hillrom, potential challenges in meeting margin expectations, and a less favorable business composition and cost environment, leading to a 3.82% decrease in stock price.
- Summary: Baxter International Inc. (BAX) experienced a -3.82% decrease in stock price, with analysts giving mixed ratings and target prices for the company. The stock price decline may be attributed to factors such as lowered price targets from research firms like Citigroup and Morgan Stanley, as well as overall market conditions affecting the healthcare sector.
Reason for stock decline: The stock may have gone down due to lowered price targets from research firms, such as Citigroup and Morgan Stanley, along with negative sentiment in the healthcare sector affecting stock performance.
- The article reports that Baxter International (BAX) stock was downgraded by research analysts at Morgan Stanley from "equal weight" to "underweight" with a new price target of $30.00, leading to a potential downside of 15.06% from the current price, contributing to the stock price decline.
|
| 2024-07-08 | -3.72 % |
|
| 2024-07-05 | +5.28 % |
|
| 2024-06-18 | -0.53 % |
|
| 2024-06-12 | +1.28 % |
- Goldman Sachs reiterated a Neutral rating on Baxter International (NYSE:BAX) with a price target of $36.00, expressing confidence in the company's operational fundamentals and future growth prospects, particularly in revenue and operating margins, driven by strategies such as supply chain improvements and pricing strategies, with expectations of reaching 17% operating margins by 2026, although the future of Baxter's Kidney Care division remains a crucial factor for the stock valuation due to an upcoming separation decision, as Baxter International Inc. delivered strong financial results for the first quarter of 2024 and received FDA approval for the expanded use of its Clinolipid product, positioning the company well within the Healthcare Equipment & Supplies industry and potential value opportunity, with a strong shareholder yield, consistent dividend payments, and anticipated net income growth.
|
| 2024-06-06 | +0.39 % |
|
